Jaguar Health Files 8-K on Shareholder Votes & Financials

TL;DR

Jaguar Health filed an 8-K detailing shareholder votes and financials.

AI Summary

Jaguar Health, Inc. filed an 8-K on June 21, 2024, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements. The filing also notes the company's former name, Jaguar Animal Health, Inc., which was changed on August 30, 2013.

Why It Matters

This filing provides updates on corporate actions and financial reporting, which are crucial for investors to understand the company's governance and financial health.

Risk Assessment

Risk Level: low — This is a routine filing reporting on corporate events and financial statements, not indicating new or immediate risks.

Key Players & Entities

• Jaguar Health, Inc. (company) — Registrant
• June 21, 2024 (date) — Date of Report
• Jaguar Animal Health, Inc. (company) — Former Company Name
• August 30, 2013 (date) — Date of Name Change
• 415-371-8300 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital Mar

Filing Documents

• tm2417778d1_8k.htm (8-K) — 44KB
• tm2417778d1_ex99-1.htm (EX-99.1) — 11KB
• tm2417778d1_ex99-1img001.jpg (GRAPHIC) — 13KB
• 0001104659-24-073983.txt ( ) — 248KB
• jagx-20240621.xsd (EX-101.SCH) — 3KB
• jagx-20240621_lab.xml (EX-101.LAB) — 33KB
• jagx-20240621_pre.xml (EX-101.PRE) — 22KB
• tm2417778d1_8k_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 21, 2024, Jaguar Health, Inc. (the "Company") h eld its 2024 Annual Meeting of Stockholders of the Company. Five proposals were submitted to and approved by the Company's stockholders. The proposals are described in details in the Company's proxy statement. The final results for the votes regarding each proposal are set for below, which do not reflect the 1-for-60 reverse stock split effectuated on May 23, 2024 (the "Reverse Stock Split") . 1. Proposal to elect one Class III director to the Company's board of directors to hold officer for a three-year term until the annual meeting of stockholders in 2027 and until his successor is elected and qualified. The votes regarding this proposal were as follows: For Withheld Broker Non- Votes Anula Jayasuriya 84,338,214 5,987,205 40,768,432 2. Proposal to ratify the appointment of RBSM LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 121,685,579 5,235,571 4,172,701 0 3. Proposal to approve, on a on a non-binding advisory basis, the compensation paid by the Company to named executive officers: For Against Abstained Broker Non- Votes 80,589,675 7,327,567 2,408,177 40,768,432 4. Proposal to approve an amendment and restatement of the Company's 2014 Stock Incentive Plan (the "2014 Plan") to increase the number of shares of Common Stock authorized for issuance under the 2014 Plan by 45,500,000 shares (equivalent to 758,333 shares following the Reverse Stock Split), was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 70,026,219 19,373,238 925,962 40,768,432 5. Proposal to approve a proposal to grant discretionary authority to adjourn the Annual Meeting, if necessary, to solicit additional proxies in the ev

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On June 21, 2024, the Company issued a press release announcing the results of the Annual Meeting, a copy of which is furnished as Exhibit 99.1. The information in Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing. 2

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated June 21, 2024. 104 Cover Page Interactive Data File (embedded with the inline XBRL document) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAGUAR HEALTH, INC. By: /s/ Lisa A. Conte Name: Lisa A. Conte Title: Chief Executive Officer & President Date: June 21, 2024 4